StreetInsider.com News Articles

Medpace (MEDP) PT Raised to $492 at TD Cowen

Fri, 24 Jul 2026 08:25:01 -0400

(Updated - July 24, 2026 8:25 AM EDT)

TD Cowen analyst Charles Rhyee raised the price target on Medpace (NASDAQ: MEDP) to $492.00 (from $419.00) while maintaining a Hold rating.

The analyst commented: "Pos+ B2B Color Masks Potential Metabolic Rev H/W in '27; Call commentary included pos+ color on bookings expectations (expect gross & net bookings growth Q/Q through '26 under any cancel scenario) and commercial KPIs (RFPs and win rates improving). We think MEDP's acknowledgment on metabolic/concentration mix presents potential sizable H/W to '27 rev growth. That said, non-metabolic bookings & mix appear to be improving (half 2Q bookings were oncology)."

Medpace (MEDP) PT Raised to $492 at TD Cowen

Fri, 24 Jul 2026 08:25:01 -0400

(Updated - July 24, 2026 8:25 AM EDT)

TD Cowen analyst Charles Rhyee raised the price target on Medpace (NASDAQ: MEDP) to $492.00 (from $419.00) while maintaining a Hold rating.

Medpace (MEDP) PT Raised to $600 at BMO Capital

Fri, 24 Jul 2026 08:01:45 -0400

(Updated - July 24, 2026 8:01 AM EDT)

BMO Capital analyst Sean Dodge raised the price target on Medpace (NASDAQ: MEDP) to $600.00 (from $400.00) while maintaining a Market Perform rating.

The analyst commented: "Raised '26 Guide on Strengthening Demand Into 2H; MEDP raised '26 revenue/EBITDA/EPS guidance 2.6%/3.3%/3.7% above consensus after a strong Q2. Notably, the revenue mix continues to shift from metabolic studies that were driving recent strength toward a more typical mix led by oncology/cardiology. While cancellations remain tougher to predict, management does expect gross bookings to continue accelerating in 2H, which should also improve the outlook for '27. However,

Medpace (MEDP) PT Raised to $600 at BMO Capital

Fri, 24 Jul 2026 08:01:45 -0400

(Updated - July 24, 2026 8:01 AM EDT)

BMO Capital analyst Sean Dodge raised the price target on Medpace (NASDAQ: MEDP) to $600.00 (from $400.00) while maintaining a Market Perform rating.

Medpace (MEDP) PT Raised to $609 at Truist Securities

Fri, 24 Jul 2026 07:13:52 -0400

Truist Securities analyst Jailendra Singh raised the price target on Medpace (NASDAQ: MEDP) to $609.00 (from $462.00) while maintaining a Hold rating.

Medpace (MEDP) PT Raised to $624 at Baird

Fri, 24 Jul 2026 07:09:47 -0400

Baird analyst Eric Coldwell raised the price target on Medpace (NASDAQ: MEDP) to $624.00 (from $547.00) while maintaining a Neutral rating.

Medpace (MEDP) PT Raised to $692 at RBC Capital

Fri, 24 Jul 2026 06:49:46 -0400

RBC Capital analyst Ryan Halsted raised the price target on Medpace (NASDAQ: MEDP) to $692.00 (from $484.00) while maintaining a Outperform rating.

Medpace (MEDP) PT Raised to $665 at Mizuho

Fri, 24 Jul 2026 06:38:36 -0400

Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $665.00 (from $586.00) while maintaining a Outperform rating.

Form 144 Medpace Holdings, Inc. Filed by: GEIGER JESSE J

Thu, 23 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260723/26808351.html

Form 144 Medpace Holdings, Inc. Filed by: GEIGER JESSE J

Thu, 23 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260723/26808351.html

Form 10-Q Medpace Holdings, Inc. For: Jun 30

Thu, 23 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260723/26807915.html

Form 10-Q Medpace Holdings, Inc. For: Jun 30

Thu, 23 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260723/26807915.html

Medpace (MEDP) PT Raised to $535 at Deutsche Bank

Thu, 23 Jul 2026 07:20:24 -0400

Deutsche Bank analyst Justin Bowers raised the price target on Medpace (NASDAQ: MEDP) to $535.00 (from $480.00) while maintaining a Hold rating.

Medpace Holdings (MEDP) Tops Q2 EPS by 27c; offers guidance

Wed, 22 Jul 2026 16:24:48 -0400

Medpace Holdings (NASDAQ: MEDP) reported Q2 EPS of $4.25, $0.27 better than the analyst estimate of $3.98. Revenue for the quarter came in at $707.3 million versus the consensus estimate of $690.68 million.

GUIDANCE:

Medpace Holdings sees FY2026 EPS of $17.25-$17.95, versus the consensus of $17.12. Medpace Holdings sees FY2026 revenue of $2.805-2.885 million, versus the consensus of $2.772 million.

For earnings history and earnings-related data on Medpace Holdings (MEDP) click here.

Medpace Holdings (MEDP) Tops Q2 EPS by 27c; offers guidance

Wed, 22 Jul 2026 16:24:48 -0400

GUIDANCE:

Medpace Holdings sees FY2026 EPS of $17.25-$17.95, versus the consensus of $17.12. Medpace Holdings sees FY2026 revenue of $2.805-2.885 million, versus the consensus of $2.772 million.

For earnings history and earnings-related data on Medpace Holdings (MEDP) click here.

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

Wed, 22 Jul 2026 16:15:00 -0400

Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%.
Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x.
Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period.

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

Wed, 22 Jul 2026 16:15:00 -0400

Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%.

Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x.

Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period.

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

Wed, 22 Jul 2026 16:15:00 -0400

Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%.

Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x.

Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period.

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

Wed, 22 Jul 2026 16:15:00 -0400

Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%.

Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x.

Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period.

Form 8-K Medpace Holdings, Inc. For: Jul 22

Wed, 22 Jul 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260722/26801897.html

Form 8-K Medpace Holdings, Inc. For: Jul 22

Wed, 22 Jul 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260722/26801897.html

Medpace (MEDP) PT Raised to $586 at Mizuho

Mon, 13 Jul 2026 06:43:47 -0400
Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $586.00 (from $495.00) while maintaining a Outperform rating.

Baird Downgrades Medpace (MEDP) to Neutral

Wed, 08 Jul 2026 03:13:23 -0400

Baird analyst Eric Coldwell downgraded Medpace (NASDAQ: MEDP) from Outperform to Neutral with a price target of $547.00 (from $477.00).
The analyst comments: “We upgraded at a lower price, and shares rallied despite rough edges with the last couple of prints. Against some modeling uncertainty, we’d either have to raise our prior price target ~$180 or raise our (still below Street) estimates materially more than we are today to put a fresh buy on here. MEDP stock is a Yo-Yo and day-of-reporting up/down trades are utter madness. This is more about NT uncertainty and relative positioning than about concerns that MEDP

Baird Downgrades Medpace (MEDP) to Neutral

Wed, 08 Jul 2026 03:13:23 -0400

Baird analyst Eric Coldwell downgraded Medpace (NASDAQ: MEDP) from Outperform to Neutral with a price target of $547.00 (from $477.00).
The analyst comments: “We upgraded at a lower price, and shares rallied despite rough edges with the last couple of prints. Against some modeling uncertainty, we’d either have to raise our prior price target ~$180 or raise our (still below Street) estimates materially more than we are today to put a fresh buy on here. MEDP stock is a Yo-Yo and day-of-reporting up/down trades are utter madness. This is more about NT uncertainty and relative positioning than about concerns that MEDP

Jefferies Downgrades Medpace (MEDP) to Hold

Tue, 07 Jul 2026 03:34:14 -0400

Jefferies analyst David Windley downgraded Medpace (NASDAQ: MEDP) from Buy to Hold with a price target of $515.00 (from $490.00).
The analyst comments: “At 30x '27 EPS and 26x '27 FCFe, valuation implies a significant growth acceleration and upward revisions. Key to that is a B2B solidly above 1.0x driving backlog growth. We think 3Q is more likely timing for that, given mgt's description of elevated cxls in 1Q26—both within backlog (~5%, highest of last yr) and, more notably, pre backlog. MEDP's reservoir of potential bookings seems depleted, making sequential backlog growth unlikely. While this is not a new issue, valuation